select trial glp 1 EFFECT OF THE GLP-1 RECEPTOR AGONIST SEMAGLUTIDE ON TOTAL CARDIOVASCULAR EVENTS IN PATIENTS WITH CARDIOVASCULAR DISEASE AND OVERWEIGHT OR OBESITY BUT NO DIABETES IN THE GLP-1 receptor agonists show promise

Patients should be counselled before starting treatment that gastrointestinal symptoms are common, particularly in the early weeks, and that they often diminish over time as the body adjusts to the medication

A 2022 meta-analysis found green tea polyphenols may improve insulin sensitivity and fasting glucose, but did not measure GLP-1 directly

I believe this is a long-term behavioral shift, not a short-term blip

Coffee consumption and risk of type 2 diabetes

People opting out of drinking not because of substance abuse issues, but because they feel its better for them still may feel uncomfortable when they elect for a mocktail, says Crain